Envestnet Portfolio Solutions Inc. Has $7.46 Million Stock Position in Zoetis Inc. $ZTS

Envestnet Portfolio Solutions Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 17.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 59,257 shares of the company’s stock after acquiring an additional 8,762 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Zoetis were worth $7,456,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Global Wealth Strategies & Associates acquired a new position in Zoetis in the fourth quarter valued at $25,000. KERR FINANCIAL PLANNING Corp bought a new position in shares of Zoetis during the 3rd quarter worth approximately $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $30,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Morgan Stanley restated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Stifel Nicolaus set a $105.00 price target on shares of Zoetis in a research note on Friday, May 8th. UBS Group decreased their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $134.75.

Zoetis Trading Up 0.9%

Shares of ZTS opened at $79.64 on Thursday. The business has a 50-day moving average of $109.69 and a 200 day moving average of $119.37. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The firm has a market cap of $33.39 billion, a P/E ratio of 13.21, a price-to-earnings-growth ratio of 1.29 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the previous year, the firm earned $1.48 EPS. The company’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Insider Activity

In related news, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.